Oregon PDAB Meeting Highlights Diverse Perspectives on UPLs
On July 24, 2024, the Oregon Prescription Drug Affordability Board (PDAB) held seven panels related to upper payment limits (UPLs),…
Browsing: Drug Pricing: Policy Activity
New White Paper Explains Why AFP Savings May Fall Short of Expectations
A new White Paper titled “Pharmacy Benefit Alternative Funding Programs: Key Considerations for Self-Funded Plan Sponsors” details how the saving…
FTC Report Unveils PBM Impact on Drug Costs and Accessibility
On July 9, 2024, the Federal Trade Commission (FTC) released an interim report highlighting the significant impact of pharmacy benefit…
Aimed Alliance Provides Comment on Medicare Drug Price Negotiation Program Guidance
On July 2, 2024, Aimed Alliance submitted a comment to the Centers for Medicare & Medicaid Services (CMS) regarding the…
Oregon PDAB Postpones Drug Reviews Until 2025
On June 26, 2024, the Oregon Prescription Drug Affordability Board (PDAB) voted to pause all ongoing drug reviews for the…
Colorado’s PDAB Declares Third Drug Unaffordable
On June 14, the Colorado Prescription Drug Affordability Board (PDAB) voted that a prescription drug used to treat various forms…
Aimed Alliance Releases New PDAB Fact Sheet: Challenges and Alternatives
On May 31, 2024, Aimed Alliance released a new fact sheet on prescription drug affordability boards (PDABs). The new resource…
Governor Signs Bill to Reform Prior Authorization Practices in Vermont
On May 20, 2024, Governor Phil Scott signed H.766, which aims to reform prior authorization practices and reduce administrative delays…
Maryland’s PDAB Initiates Cost Review for Six Drugs
On May 20, 2024, Maryland’s Prescription Drug Affordability Board (PDAB) voted to initiate cost review and affordability studies for six…
Aimed Alliance Sends Letter on Nebraska’s PDAB Proposal
On May 7, 2024, Aimed Alliance submitted a letter to the Nebraska Banking, Commerce, and Insurance Committee regarding L.B.33, which…